Table 2. Extent of available surveillance data to assess effectiveness of RSV vaccine for public health priorities by target groups.
| Public health priority | Public health parameters Measures used by NACI to assess burden of illness |
||||
|---|---|---|---|---|---|
| Incidence | Study settingsa |
Virus strain | High risk populationsb |
||
| Infant hospitalization | IMPACTc CIHIc |
IMPACTc CIHIc |
IMPACTd | IMPACTd | CIHIc |
| Infant death | IMPACTc CIHIc |
IMPACTc CIHIc |
IMPACTd | IMPACTd | CIHIc |
| Infection in remote communities (child) | IMPACTc CIHIc |
IMPACTc CIHIc |
IMPACTc | IMPACTc CIHIc |
|
| Child hospitalization | IMPACTc CIHIc |
IMPACTc CIHIc |
IMPACTd | IMPACTd | CIHIc |
| Child death | IMPACTc CIHIc |
IMPACTc CIHIc |
IMPACTd | IMPACTd | CIHIc |
| Senior hospitalization | CIHIc | CIHIc | NDe | CIHIc | |
| Senior death | CIHIc | CIHIc | NDe | CIHIc | |
Abbreviations: CIHI, Canadian Institute for Health Information; IMPACT, Immunization Monitoring Program ACTive; NACI, National Advisory Committee on Immunization; ND, no data; RSV, respiratory syncytial virus
a Study settings may include: community, primary care, hospital, nosocomial
b High risk populations for RSV include: infants, children and seniors with underlying medical conditions
c Limited data - yellow
d Sufficient data - grey
e No data - pink